In adults with heart failure with preserved ejection fraction (HFpEF), does treatment with an SGLT2 inhibitor reduce heart-failure hospitalisation or cardiovascular mortality compared with standard therapy alone?
Abstract
SGLT2 inhibitors appear to reduce hospitalisations for heart failure in HFpEF patients, but their effect on cardiovascular mortality is less certain.
Fields of Study & Subjects
Heart Failure Treatment and Management
Diabetes Treatment and Management
Cardiovascular Function and Risk Factors
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 16 March 2026
- Language
- EN